Union City, CA, United States of America

Pearl Shwe-Cho Tay

USPTO Granted Patents = 1 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Pearl Shwe-Cho Tay: A Pioneer in Bruton's Tyrosine Kinase Inhibition

Introduction: Pearl Shwe-Cho Tay, an inventive mind based in Union City, California, has made significant contributions to the field of pharmaceuticals. With a focus on a targeted approach to autoimmune diseases, cancers, and inflammatory conditions, Tay's work exemplifies the impactful role of innovative thinkers in the medical landscape.

Latest Patents: Tay holds a patent concerning Bruton's tyrosine kinase (Btk) inhibitors. The patent titled "Formulations of a Bruton's Tyrosine Kinase Inhibitor" describes a novel pharmaceutical formulation known as 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. This invention not only details the inhibitor itself but also covers various pharmaceutical compositions containing it. The applications of this Btk inhibitor extend to the treatment of autoimmune diseases, heteroimmune diseases, different cancers including lymphoma, and various inflammatory conditions.

Career Highlights: Throughout his career, Pearl Shwe-Cho Tay has been associated with Pharmacyclics, Inc., a biopharmaceutical company known for its commitment to developing innovative therapies. His expertise in pharmacology has driven advancements in targeting specific pathways involved in disease processes, leading to improved therapeutic outcomes for patients.

Collaborations: In his professional journey, Tay has collaborated with talented colleagues such as Cassandra Shu and Harisha Atluri. These collaborations emphasize the importance of teamwork in research and development, pooling together knowledge and expertise to foster innovations.

Conclusion: Pearl Shwe-Cho Tay's innovations in formulating Btk inhibitors reflect a commitment to addressing pressing health challenges through scientific advancement. His work at Pharmacyclics, Inc., alongside esteemed coworkers, showcases the collaborative spirit needed to push the boundaries of modern medicine and provide solutions for complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…